TD Asset Management Inc Has $2.92 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE

TD Asset Management Inc lowered its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 21.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 96,998 shares of the biopharmaceutical company’s stock after selling 26,886 shares during the quarter. TD Asset Management Inc’s holdings in Ultragenyx Pharmaceutical were worth $2,918,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Covestor Ltd increased its holdings in shares of Ultragenyx Pharmaceutical by 26.0% during the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 369 shares in the last quarter. Teacher Retirement System of Texas grew its position in Ultragenyx Pharmaceutical by 1.8% during the 2nd quarter. Teacher Retirement System of Texas now owns 22,773 shares of the biopharmaceutical company’s stock worth $828,000 after acquiring an additional 404 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Ultragenyx Pharmaceutical by 2.3% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,988 shares of the biopharmaceutical company’s stock valued at $690,000 after purchasing an additional 434 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in Ultragenyx Pharmaceutical by 7.0% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,783 shares of the biopharmaceutical company’s stock valued at $247,000 after purchasing an additional 441 shares during the last quarter. Finally, DNB Asset Management AS boosted its stake in Ultragenyx Pharmaceutical by 3.2% in the second quarter. DNB Asset Management AS now owns 14,720 shares of the biopharmaceutical company’s stock worth $535,000 after purchasing an additional 452 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, CAO Theodore Alan Huizenga sold 1,632 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $37,209.60. Following the completion of the sale, the chief accounting officer owned 48,670 shares of the company’s stock, valued at $1,109,676. This represents a 3.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Emil D. Kakkis sold 54,404 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $1,240,411.20. Following the sale, the chief executive officer owned 658,994 shares in the company, valued at approximately $15,025,063.20. The trade was a 7.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 108,039 shares of company stock worth $2,506,945 in the last quarter. Company insiders own 5.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on RARE shares. Robert W. Baird decreased their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a report on Tuesday, December 30th. Leerink Partners lowered their price target on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Tuesday, December 30th. Truist Financial dropped their price objective on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Wells Fargo & Company decreased their price objective on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 30th. Finally, TD Cowen lowered their target price on Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Sixteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $68.29.

Ultragenyx Pharmaceutical Trading Down 1.2%

Shares of Ultragenyx Pharmaceutical stock opened at $21.80 on Thursday. The stock’s fifty day simple moving average is $23.56 and its 200 day simple moving average is $29.19. The company has a market capitalization of $2.11 billion, a PE ratio of -3.73 and a beta of 0.16. Ultragenyx Pharmaceutical Inc. has a 12 month low of $18.41 and a 12 month high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.09). The business had revenue of $207.28 million during the quarter, compared to the consensus estimate of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The firm’s revenue was up 25.5% compared to the same quarter last year. During the same quarter last year, the company earned ($1.39) earnings per share. Analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.